Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance

Critical Care

Volumn 20, Issue 1, 2016, Pages

  Opal, Steven M ^a,b  

^a BROWN UNIVERSITY   (United States)

^b Ocean State Clinical Coordinating Center   (United States)

Author keywords

Antibiotic resistance; Monoclonal antibodies to treat bacterial infections; Novel therapies for bacterial infections; Phage therapy; Quorum sensing inhibitors

Indexed keywords

ANTIINFECTIVE AGENT; QUORUM SENSING INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BACTERIOLYSIS; BACTERIOPHAGE; EBOLAVIRUS; EDITORIAL; GENE; GENE EXPRESSION; HEMOFILTRATION; HEMOFILTRATION DEVICE; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOTHERAPY; LYTIC BACTERIOPHAGE; MEDICAL DEVICE; MULTIDRUG RESISTANCE; NON IMMUNE TOLERANCE; NONHUMAN; PHAGE THERAPY; PRIORITY JOURNAL; TEK GENE; PATHOGENICITY; PROCEDURES; QUORUM SENSING; STANDARDS;

BACTERIAL INFECTIONS; BACTERIOPHAGES; DRUG RESISTANCE, BACTERIAL; HEMOFILTRATION; HUMANS; PHAGE THERAPY; QUORUM SENSING; THERAPEUTICS;

EID: 85005949352     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-016-1549-1     Document Type: Editorial

References (15)

1. Rolain JM, Parola P, Cornaglia C. New Delhi metallo-beta lactamase (NDM-1): towards a new pandemic? Clin Microbial Infect. 2010;16(12):1699-76.
2. Liu Y-Y, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism, MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):160-8.
3. McCrea K, Ward R, LaRosa S. Removal of carbapenem-resistant Enterobacteriaceae (CRE) from blood by heparin-functional hemoperfusion media. PLoS One. 2014;9(12), e114242.
4. Kang JH, Super M, Yung CW, et al. An extracorporeal blood-cleaning device for sepsis therapy. Nat Med. 2014;20:1211-6.
5. Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Curr Pharm Des. 2015;21(1):5-11.
6. Kalia V. Quorum sensing inhibitors: an overview. Biotechnol Adv. 2013;31(2):224-45.
7. Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol. 2009;34(4):349-57.
8. Wittebole X, De Roock S, Opal S. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence. 2014;5(1):226-35.
9. Irani V, Guy A, Andrew D, et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mole Immun. 2015;67:171-82.
10. Lu Q, Rouby JJ, Laterre PF, et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa 011 pneumonia. J Antimicrob Chemother. 2011;66(5):1110-6.
11. Luke T, Wu H, Zhao J, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoA in vivo. Sci Transl Med. 2016;8(326):326ra21.
12. Boomer J, To K, Chang K, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-605.
13. Henry B, Neill D, Becker K, et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol. 2015;33(1):81-8.
14. Medzhitov R, Schneider D, Soares M. Disease tolerance as a strategy. Science. 2012;335(6071):936-14.
15. Rassmussen AL, Okumura A, Ferris MT, et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science. 2014;346(6212):987-91.